Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria

Expert Review of Clinical Pharmacology

Volumn 8, Issue 1, 2014, Pages 43-53

  Minder, Elisabeth I ^a   Schneider Yin, Xiaoye ^a  

^a Institute of Laboratory Medicine Stadtspital Triemli   (Switzerland)

Author keywords

afamelanotide; clinical trials; orphan disease; protoporphyria; melanocyte stimulating hormone

Indexed keywords

AFAMELANOTIDE; ALPHA INTERMEDIN; MELANIN; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN RECEPTOR; PORPHYRIN; PROOPIOMELANOCORTIN;

ARTICLE; CAUCASIAN; COMPARATIVE STUDY; COMPASSIONATE USE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; ERYTHROPOIETIC PROTOPORPHYRIA; FLUSHING; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HUMAN; IMMUNOGENICITY; LONG TERM CARE; MELANOMA; METABOLISM; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHOTOTOXICITY; PORPHYRIA; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SKIN PROTECTION; SWITZERLAND; VOMITING; ANALOGS AND DERIVATIVES; INTRADERMAL DRUG ADMINISTRATION; PROTOPORPHYRIA, ERYTHROPOIETIC; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, CUTANEOUS; ALPHA-MSH; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; PROTOPORPHYRIA, ERYTHROPOIETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84916940347     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.956089     Document Type: Article

References (115)

1. Jong CT, Finlay AY, Pearse AD, et al. The quality of life of 790 patients with photodermatoses. Br J Dermatol 2008; 159(1):192-7
2. Collins P, Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995; 132(6):956-63
3. Nordlund JJ, Boissy RE, Haering VJ, et al. The pigmentary system: physiology and pathophysiology. Blackwell Publishing Ltd; Oxford UK. 2nd edition. 2006
4. Bohm M, Luger TA, Tobin DJ, Garcia-Borron JC. Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol 2006;126(9):1966-75
5. Song X, Mosby N, Yang J, et al. alpha-MSH activates immediate defense responses to UV-induced oxidative stress in human melanocytes. Pigment Cell Melanoma Res 2009;22:809-18
6. Gilchrest BA, Park HY, Eller MS, Yaar M. Mechanisms of ultraviolet light-induced pigmentation. Photochem Photobiol 1996;63:1-10
7. Cui R, Widlund HR, Feige E, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007;128:853-64
8. Barsh G, Attardi LD. A healthy tan? N Engl J Med 2007;356:2208-10
9. Armstrong BK, Kricker A, English DR. Sun exposure and skin cancer. Australas J Dermatol 1997;38(Suppl 1):S1-6
10. Landi MT, Baccarelli A, Calista D, et al. Combined risk factors for melanoma in a Mediterranean population. Br J Cancer 2001;85:1304-10
11. Richmond-Sinclair NM, Pandeya N, Ware RS, et al. Incidence of basal cell carcinoma multiplicity and detailed anatomic distribution: longitudinal study of an Australian population. J Invest Dermatol 2009;129:323-8
12. Crombie IK. Racial differences in melanoma incidence. Br J Cancer 1979;40: 185-93
13. Crombie IK. Variation of melanoma incidence with latitude in North America and Europe. Br J Cancer 1979;40:774-81
14. Mackie RM, Bray CA, Hole DJ, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002;360:587-91
15. Healy E, Jordan SA, Budd PS, et al. Functional variation of MC1R alleles from red-haired individuals. Hum Mol Genet 2001;10:2397-402
16. Makova K, Norton H. Worldwide polymorphism at the MC1R locus and normal pigmentation variation in humans. Peptides 2005;26:1901-8
17. Rouzaud F, Kadekaro AL, Abdel-Malek ZA, Hearing VJ. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res 2005;571:133-52
18. Rees JL. Genetics of hair and skin color. Annu Rev Genet 2003;37:67-90
19. Sturm RA, Duffy DL, Box NF, et al. Genetic association and cellular function of MC1R variant alleles in human pigmentation. Ann N Y Acad Sci 2003;994: 348-58
20. Ha T, Naysmith L, Waterston K, et al. Defining the quantitative contribution of the melanocortin 1 receptor (MC1R) to variation in pigmentary phenotype. Ann N Y Acad Sci 2003;994:339-47
21. Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11:328-30
22. Luger TA, Scholzen T, Grabbe S. The role of alpha-melanocyte-stimulating hormone in cutaneous biology. J Investig Dermatol Symp Proc 1997;2:87-93
23. Luger TA, Scholzen T, Brzoska T, et al. Cutaneous immunomodulation and coordination of skin stress responses by alpha-melanocyte-stimulating hormone. Ann N Y Acad Sci 1998;840:381-94
24. Palmer JS, Duffy DL, Box NF, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66:176-86
25. April CS, Barsh GS. Distinct pigmentary and melanocortin 1 receptor-dependent components of cutaneous defense against ultraviolet radiation. PLoS Genet 2007;3:e9
26. Robinson S, Dixon S, August S, et al. Protection against UVR Involves MC1R-Mediated Non-Pigmentary and Pigmentary Mechanisms In Vivo. J Invest Dermatol 2010;130(7):1904-13
27. Abdel-Malek ZA, Ruwe A, Kavanagh-Starner R, et al. alpha-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes. Pigment Cell Melanoma Res 2009;22: 635-44
28. Dong L, Wen J, Pier E, et al. Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism. Cancer Res 2010;70:3547-56
29. Bohm M, Wolff I, Scholzen TE, et al. alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem 2005;280:5795-802
30. Kokot A, Metze D, Mouchet N, et al. Alpha-melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology 2009;150: 3197-206
31. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev 2006;27:736-49
32. Wikberg JE. Melanocortin receptors: perspectives for novel drugs. Eur J Pharmacol 1999;375:295-310
33. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides 2006;27:921-30
34. Kadekaro AL, Wakamatsu K, Ito S, Abdel-Malek ZA. Cutaneous photoprotection and melanoma susceptibility: reaching beyond melanin content to the frontiers of DNA repair. Front Biosci 2006;11:2157-73
35. Gantz I, Konda Y, Tashiro T, et al. Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993;268:8246-50
36. Gantz I, Miwa H, Konda Y, et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993;268:15174-9
37. Spencer JD, Schallreuter KU. Regulation of pigmentation in human epidermal melanocytes by functional high-affinity beta-melanocyte-stimulating hormone/ melanocortin-4 receptor signaling. Endocrinology 2009;150:1250-8
38. Rodrigues AR, Almeida H, Gouveia AM. Alpha-MSH signalling via melanocortin 5 receptor promotes lipolysis and impairs re-esterification in adipocytes. Biochim Biophys Acta 2013;1831:1267-75
39. Krude H, Biebermann H, Luck W, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998;19:155-7
40. Beaumont KA, Shekar SN, Cook AL, et al. Red hair is the null phenotype of MC1R. Hum Mutat 2008;29:E88-94
41. Ghanem G, Verstegen J, Libert A, et al. Alpha-melanocyte-stimulating hormone immunoreactivity in human melanoma metastases extracts. Pigment Cell Res 1989;2:519-23
42. Ghanem G, Verstegen J, De Rijcke S, et al. Studies on factors influencing human plasma alpha-MSH. Anticancer Res 1989;9: 1691-6
43. Nagahama M, Funasaka Y, Fernandez-Frez ML, et al. Immunoreactivity of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and beta-endorphin in cutaneous malignant melanoma and benign melanocytic naevi. Br J Dermatol 1998;138:981-5
44. Sheppard JR, Koestler TP, Corwin SP, et al. Experimental metastasis correlates with cyclic AMP accumulation in B16 melanoma clones. Nature 1984;308:544-7
45. Lunec J, Pieron C, Thody AJ. MSH receptor expression and the relationship to melanogenesis and metastatic activity in B16 melanoma. Melanoma Res 1992;2:5-12
46. Bennett DC, Dexter TJ, Ormerod EJ, Hart IR. Increased experimental metastatic capacity of a murine melanoma following induction of differentiation. Cancer Res 1986;46:3239-44
47. Abdel-Malek Z, Swope VB, Suzuki I, et al. Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci U S A 1995;92:1789-93
48. Murata J, Ayukawa K, Ogasawara M, et al. Alpha-melanocyte-stimulating hormone blocks invasion of reconstituted basement membrane (Matrigel) by murine B16 melanoma cells. Invasion Metastasis 1997;17:82-93
49. Eves P, Haycock J, Layton C, et al. Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. Br J Cancer 2003;89:2004-15
50. Eves PC, MacNeil S, Haycock JW. alpha-Melanocyte stimulating hormone, inflammation and human melanoma. Peptides 2006;27:444-52
51. Gray-Schopfer VC, Cheong SC, Chong H, et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 2006;95:496-505
52. Osawa M, Egawa G, Mak SS, et al. Molecular characterization of melanocyte stem cells in their niche. Development 2005;132:5589-99
53. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328-37
54. Ackermann J, Frutschi M, Kaloulis K, et al. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 2005;65:4005-11
55. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65:4320-33
56. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008;451:345-9
57. Jiang J, Sharma SD, Nakamura S, et al. The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation. Pigment Cell Res 1995;8:314-23
58. Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 2008;21:27-38
59. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006;355:51-65
60. Anderson K, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. 2001;8:2991-3062
61. Schneider-Yin X, Gouya L, Meier-Weinand A, et al. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr 2000;159:719-25
62. Lecha M, Puy H, Deybach JC. Erythropoietic protoporphyria. Orphanet J Rare Dis 2009;4:19
63. Went LN, Klasen EC. Genetic aspects of erythropoietic protoporphyria. Ann Hum Genet 1984;48:105-17
64. Gouya L, Puy H, Robreau AM, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 2002;30: 27-8
65. Whatley SD, Mason NG, Holme SA, et al. Molecular epidemiology of erythropoietic protoporphyria in the U.K. Br J Dermatol 2010;162:642-6
66. Gouya L, Puy H, Lamoril J, et al. Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation. Blood 1999;93:2105-10
67. Whatley SD, Ducamp S, Gouya L, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008;83: 408-14
68. Clark KG, Nicholson DC. Erythrocyte protoporphyrin and iron uptake in erythropoietic protoporphyria. Clin Sci 1971;41:363-70
69. Brun A, Western A, Malik Z, Sandberg S. Erythropoietic protoporphyria: photodynamic transfer of protoporphyrin from intact erythrocytes to other cells. Photochem Photobiol 1990;51:573-7
70. Ibrahim GW, Watson CJ. Enterohepatic circulation and conversion of protoporphyrin to bile pigment in man. Proc Soc Exp Biol Med 1968;127:890-5
71. Afonso S, Vanore G, Batlle A. Protoporphyrin IX and oxidative stress. Free Radic Res 1999;31:161-70
72. Magnus IA, Jarrett A, Prankerd TA, Rimington C. Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet 1961;2:448-51
73. Goldstein BD, Harber LC. Erythropoietic protoporphyria: lipid peroxidation and red cell membrane damage associated with photohemolysis. J Clin Invest 1972;51: 892-902
74. Bagdonas S, Ma LW, Iani V, et al. Phototransformations of 5-aminolevulinic acid-induced protoporphyrin IX in vitro: a spectroscopic study. Photochem Photobiol 2000;72:186-92
75. Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol 1981;77: 13-19
76. Parrish JA, Rosen CF, Gange RW. Therapeutic uses of light. Ann N Y Acad Sci 1985;453:354-64
77. Timonen K, Kariniemi AL, Niemi KM, et al. Vascular changes in erythropoietic protoporphyria: histopathologic and immunohistochemical study. J Am Acad Dermatol 2000;43:489-97
78. Lim HW. Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria. Immunol Ser 1989;46: 671-85
79. Lim HW. Pathogenesis of photosensitivity in the cutaneous porphyrias. J Invest Dermatol 2005;124:xvi-xvii
80. Poh-Fitzpatrick MB. The "priming phenomenon" in the acute phototoxicity of erythropoietic protoporphyria. J Am Acad Dermatol 1989;21:311
81. Rufener EA. ["⋯ and found no shade". Coping processes of patients with erythropoietic protoporphyria]. Psychother Psychosom Med Psychol 1992;42:339-48
82. Rufener EA. Erythropoietic protoporphyria: a study of its psychosocial aspects. Br J Dermatol 1987;116:703-8
83. Minder EI. Afamelanotide, an agonistic analog of alpha-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. Expert Opin Investig Drugs 2010;19:1591-602
84. Minder EI, Schneider-Yin X, Steuer J, Bachmann LM. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-legrand) 2009;55:84-97
85. Corbett MF, Herxheimer A, Magnus IA, et al. The long term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br J Dermatol 1977;97:655-62
86. Holme SA, Anstey AV, Finlay AY, et al. Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol 2006;155:574-81
87. Wahlin S, Floderus Y, Stal P, Harper P. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med 2011;269:278-88
88. Murphy GM, Hawk JL. Erythropoietic protoporphyria advances today, with a special tribute to the late Professor Ian Magnus. Br J Dermatol 2006;155:501-3
89. Wahlin S, Srikanthan N, Hamre B, et al. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transpl 2008;14: 1340-6
90. Pawliuk R, Bachelot T, Wise RJ, et al. Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 1999;5: 768-73
91. Pawliuk R, Tighe R, Wise RJ, et al. Prevention of murine erythropoietic protoporphyria-associated skin photosensitivity and liver disease by dermal and hepatic ferrochelatase. J Invest Dermatol 2005;124:256-62
92. Oustric V, Manceau H, Ducamp S, et al. Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria. Am J Hum Genet 2014;94:611-17
93. Poh-Fitzpatrick MB, Wang X, Anderson KE, et al. Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. J Am Acad Dermatol 2002;46: 861-6
94. Rand EB, Bunin N, Cochran W, et al. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 2006;118:e1896-9
95. Wahlin S, Harper P. Pretransplant albumin dialysis in erythropoietic protoporphyria: a costly detour. Liver Transpl 2007;13: 1614-15
96. Ugwu SO, Blanchard J, Dorr RT, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos 1997;18:259-69
97. Bhardwaj R, Hadley ME, Dorr RT, et al. Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog. Melanotan-I. Pharm Res 2000;17: 593-9
98. Dwyer T, Blizzard L, Ashbolt R, et al. Cutaneous melanin density of Caucasians measured by spectrophotometry and risk of malignant melanoma, basal cell carcinoma, and squamous cell carcinoma of the skin. Am J Epidemiol 2002;155:614-21
99. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 7-D-phenylalanine-alpha-melanocytestimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A 1980;77: 5754-8
100. Frandberg PA, Muceniece R, Prusis P, et al. Evidence for alternate points of attachment for alpha-MSH and its stereoisomer [Nle4, D-Phe7]-alpha-MSH at the melanocortin-1 receptor. Biochem Biophys Res Commun 1994;202:1266-71
101. Yang Y, Dickinson C, Haskell-Luevano C, Gantz I. Molecular basis for the interaction of [Nle4,D-Phe7]melanocyte stimulating hormone with the human melanocortin-1 receptor. J Biol Chem 1997;272:23000-10
102. Abdel-Malek ZA, Kadekaro AL, Kavanagh RJ, et al. Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J 2006;20:1561-3
103. Kadekaro AL, Kavanagh R, Kanto H, et al. alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res 2005;65:4292-9
104. Newton RA, Smit SE, Barnes CC, et al. Activation of the cAMP pathway by variant human MC1R alleles expressed in HEK and in melanoma cells1. Peptides 2005;26: 1818-24
105. Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM. Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides 2006;27:388-394
106. Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocytestimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006;126:1869-78
107. Lengweiler S, Kreim S, Barman-Aksözen J, et al. Evaluation of the Immunogenicity of the Synthetic a-Melanocyte-Stimulating Hormone (MSH) Analogue Afamelanotide ([Nle4, D-Phe7]-a-MSH, SCENESSE) in Erythropoietic Protoporphyria Patients by ELISA detecting both anti-afamelanotide and anti-a-MSH antibodies. Skin Pharmacology and Physiology; in press
108. Spichty R, Balimann M, Barman J, Minder EI. A bioassay for detection of neutralizing antibodies against the alpha-melanocyte stimulating hormone analogue afamelanotide in patients with erythropoietic protoporphyria. J Pharm Biomed Anal 2013;75:192-8
109. Minder EI. Afamelanotide. Drugs Fut 2010;35:365-72
110. Grimes PE, Hamzavi I, Lebwohl M, et al. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol 2013;149:68-73
111. Biolcati G, Aurizi C, Barbieri L, et al. Efficacy of the melanocortin analogue Nle4- D-Phe7-alpha-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clin Exp Dermatol 2014;39:168-75
112. Harms J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 2009;360:306-7
113. Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol 2009;85:1434-9
114. Minder EI, Harms J, Lautenschlager S, et al. A double-blind, randomized, controlled phase III trial of afamelanotide (an -MSH-analogue) in erythropoietic protoporphyria (EPP) - preliminary data on a Swiss cohort of patients and a model to determine efficacy in EPP. Berzelius symposium 81-Porphyrins and Porphyrias; 14 - 18 June 2009; Stockholm; 2009
115. Mathews-Roth MM, Pathak MA, Fitzpatrick TB, et al. Beta carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases. Arch Dermatol 1977;113:1229-32